Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA33890 plus bevacizumab + FOLFOX vs placebo in first-line metastatic MSS colorectal cancer
jRCT2051250251Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing INCA33890 + bevacizumab + FOLFOX with Placebo + bevacizumab + FOLFOX (2 arms). Primary endpoint: Progression-Free Survival. Started Jun 2026; status: recruiting.
02
Drugs
INCA-33890
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2051250251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250251.